| Deal value | $100M |
|---|---|
| Share of market cap | 28.3% |
Key highlights
- Issuance of 22,040,976 shares of common stock at a public price of $3.87 per share
- Offering includes 3,800,000 pre-funded warrants at $3.869 per warrant for certain investors
- Expected net proceeds of $93.5 million after deducting underwriting discounts and commissions
- Financing led by Frazier Life Sciences with participation from new and existing funds
- Capital reserved for ersodetug commercialization, working capital, and general corporate purposes
What Is the Capital Raise?
Rezolute, Inc. entered into a definitive underwriting agreement for the issuance and sale of 22,040,976 shares of common stock at a public offering price of $3.87 per share. To accommodate specific institutional requirements, the company also issued 3,800,000 pre-funded warrants at $3.869 each, which represents the share price minus a nominal $0.001 exercise price. The transaction, set to close around November 16, 2026, involves Morgan Stanley, Guggenheim Securities, and Cantor Fitzgerald & Co. as joint book-running managers. The financing was anchored by Frazier Life Sciences and included participation from several institutional funds.
Down 2.1% since our story on 16 Nov: $3.65 when we broke it → $3.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $3.70 |
|---|---|
| 20 Oct | $3.70 |
| 21 Oct | $3.70 |
| 22 Oct | $3.86 |
| 23 Oct | $3.85 |
| 26 Oct | $3.82 |
| 27 Oct | $4.11 |
| 28 Oct | $4.22 |
| 29 Oct | $4.12 |
| 30 Oct | $3.95 |
| 2 Nov | $3.88 |
| 3 Nov | $4.01 |
| 4 Nov | $3.96 |
| 5 Nov | $3.64 |
| 6 Nov | $3.88 |
| 9 Nov | $3.87 |
| 10 Nov | $4.02 |
| 11 Nov | $4.07 |
| 12 Nov | $3.87 |
| 13 Nov | $3.65 |
| 16 Nov | $3.58 |
Use of Proceeds
- Preparing the logistical and marketing infrastructure for ersodetug commercialization
- Funding late-stage clinical operations and metabolic disease research and development
- Supporting general working capital requirements to maintain daily operations
- Meeting administrative and corporate expenses necessary for scale-up
- Strengthening the balance sheet against future regulatory or clinical milestones
Strategic Rationale
The capital injection arrives as Rezolute transitions toward a commercial-stage pharmaceutical entity. By securing $100 million, the company establishes a financial runway to support the launch of ersodetug, an antibody therapy for refractory hypoglycemia. This rare metabolic condition currently lacks adequate long-term treatment options, positioning Rezolute to address a high-need orphan market. The involvement of specialized healthcare investors like Frazier Life Sciences provides a layer of institutional validation for the company's clinical pipeline and commercial strategy, reducing the reliance on near-term debt financing while maintaining focus on its flagship metabolic asset.
Business Overview
Based in Redwood City, California, Rezolute is a late-stage biotechnology firm dedicated to ultra-rare metabolic diseases. The company's primary focus is refractory hypoglycemia caused by hyperinsulinism, a condition where excessive insulin production leads to dangerously low blood sugar levels. Its lead candidate, ersodetug, is an insulin receptor monoclonal antibody that has demonstrated potential in clinical trials and real-world usage. By modulating the insulin receptor, the therapy aims to provide a stable therapeutic window for patients who have failed existing treatments, targeting a significant unmet need in the pediatric and adult metabolic healthcare space.
| Share price | $3.65 |
|---|---|
| Market cap | $354M |
| 1-month price change | -13.59% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Rezolute, Inc. announcing the pricing of an underwritten public offering of common stock and pre-funded warrants.
Track Rezolute, Inc. live
Get the next Rezolute, Inc. SEC filing seconds after it lands.




